Stockscreener 앱 받기
87.41
0.41%
-0.36
시간 외 거래:
87.46
0.05
+0.06%
전일 마감가:
$87.77
열려 있는:
$87.92
하루 거래량:
9.52M
Relative Volume:
0.80
시가총액:
$152.25B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
24.35
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+3.48%
1개월 성능:
-4.68%
6개월 성능:
-31.77%
1년 성능:
-33.53%
1일 변동 폭
$87.05
$88.84
1주일 범위
$84.40
$89.34
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Reassessing Abbott Laboratories (ABT) After A 32% One Year Share Price Decline - Yahoo Finance
Abbott Deepens Digital Health Push With New Cardiovascular Diagnostics And Wearables - simplywall.st
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity - Barchart
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - AOL.com
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum - Insider Monkey
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT) - Insider Monkey
Three Recession-Resistant Stocks Worth Investors’ Attention - NAI500
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story - Yahoo Finance
Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026News and Statistics - IndexBox
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Long term debt to total equity ratio of Abbott Laboratories – BVL:ABTUS - TradingView
Abbott Laboratories Balance Sheet – BVL:ABTUS - TradingView
Buying pulsed field ablation systems: What hospitals should know - Modern Healthcare
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
3 Stocks to Buy if You Think the Economy Is Heading for a Recession - The Motley Fool
Abbott Laboratories stock (US0028241000): diabetes business and latest earnings in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimila - AD HOC NEWS
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly updat - AD HOC NEWS
Worker says Abbott fired him over a chat his coworker started - hcamag.com
ECMC debuts new high-tech blood & urine lab to cut down on processing times by 20 percent - WKBW
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit - AboutLawsuits.com
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - 富途牛牛
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu - AD HOC NEWS
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity? - simplywall.st
Build-A-Bear Workshop and Abbott Laboratories o... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Abbott Laboratories (ABT) is attracting investor attention: Here is what you should know - MSN
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review - Traders Union
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
ABT Stock Price and Chart — NYSE:ABT - TradingView
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Stock Analysis: Unlocking a 40% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc. - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum - AD HOC NEWS
Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused - AD HOC NEWS
Abbott Laboratories Stock (ABT) Opinions on Recent Price Declines - Quiver Quantitative
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories $ABT Stock Holdings Lowered by iA Global Asset Management Inc. - MarketBeat
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
0.95%
0.16%
자본화:
|
볼륨(24시간):